Dahlof 1992.

Methods	Single‐centre, randomised, double‐blind, placebo‐controlled, within‐patient cross‐over. Each participant treated 2 successive attacks with a single dose of one or other study medication. Medication administered when migraine headache pain was of moderate or severe intensity Assessments at 0.5, 1, 1.5, and 2 h after dosing Rescue medication (not ergotamine) was available after 2 h for inadequate relief of symptoms
Participants	Aged 18 to 65 years, meeting IHS criteria for migraine (1988) with or without aura. At least 1‐year history of migraine (untreated severity ≥ moderate) with an average of 1 to 6 attacks per month. Use of migraine prophylactic therapy was stopped at least 2 weeks before receipt of study medication. No ergotamine‐containing preparations within 24 h, and no analgesics within 6 h of taking study medication. Minimum of 48 h between treated attacks N = 27 M 5, F 22 (81%) Mean age 45 years Proportion with/without aura not reported
Interventions	Sumatriptan 8 mg, n = 27 Placebo, n = 27
Outcomes	Headache relief (at 1 and 2 h) Pain‐free (at 2 h) Use of rescue medication Presence of functional disability (at 1 and 2 h)
Notes	Oxford Quality Score: R1, DB2, W0. Total = 3.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) All outcomes	Low risk	Matching placebo
Study size	High risk	Treatment groups < 50 participants